Full Study Report of Andexanet Alfa for Bleeding Associated with Factor Xa Inhibitors
Work
Year: 2019
Type: article
Abstract: Andexanet alfa is a modified recombinant inactive form of human factor Xa developed for reversal of factor Xa inhibitors.We evaluated 352 patients who had acute major bleeding within 18 hours after ad... more
Source: New England Journal of Medicine
Authors Stuart J. Connolly, Mark Crowther, John W. Eikelboom, C. Michael Gibson, John T. Curnutte +24 more
Institutions McMaster University, Population Health Research Institute, Baim Institute for Clinical Research, Portola Pharmaceuticals (United States), KU Leuven +11 more
Cites: 16
Cited by: 827
Related to: 10
FWCI: 99
Citation percentile (by year/subfield): 100
Subfield: Cardiology and Cardiovascular Medicine
Field: Medicine
Domain: Health Sciences
Sustainable Development Goal Zero hunger
Open Access status: bronze
Funder Portola Pharmaceuticals